Published in final edited form as:

J Cell Physiol. 2012 November ; 227(11): 3539–3545. doi:10.1002/jcp.24075.

Role of fibroblast growth factor 2 and Wnt signaling in anabolic effects of parathyroid hormone on bone formation

Yurong Fei¹ and Marja M. Hurley^{1,*}

¹Department of Medicine, University of Connecticut Health Center, Farmington, CT, USA

Abstract

Osteoporosis poses enormous health and economic burden worldwide. One of the very few anabolic agents for osteoporosis is parathyroid hormone (PTH). Although great progress has been made since the FDA approved PTH in 2002, the detailed mechanisms of the bone anabolic effects of intermittent PTH treatment is still not well understood. PTH bone anabolic effect is regulated by extracellular factors. Maximal bone anabolic effect of PTH requires fibroblast growth factor 2 (FGF2) signaling, which might be mediated by transcription factor activating transcription factor 4 (ATF4). Maximal bone anabolic effect of PTH also requires Wnt signaling. Particularly, Wnt antagonists such as sclerostin, dickkopf 1 (DKK1) and secreted frizzled related protein 1 (sFRP1) are promising targets to increase bone formation. Interestingly, FGF2 signaling modulates Wnt/ β -Catenin signaling pathway in bone. Therefore, multiple signaling pathways utilized by PTH are cross talking and working together to promote bone formation. Extensive studies on the mechanisms of action of PTH will help to identify new pathways that regulate bone formation, to improve available agents to stimulate bone formation, and to identify potential new anabolic agents for osteoporosis.

Keywords

PTH; FGF2; Wnt signaling; ATF4

Introduction

Osteoporotic fracture is estimated to occur every 3 seconds worldwide (Johnell and Kanis, 2006). An estimated 44 million Americans are threatened by osteoporosis today. By 2025, more than 3 million osteoporotic fractures are estimated to occur in the United States alone and the cost is predicted to be approximately \$25.3 billion (NOF.). Therefore, osteoporosis is an enormous health and economic problem. Osteoporosis is a disease characterized by low bone mass and deterioration in the microarchitecture of bone tissue (Holroyd et al., 2008).

Current treatments for osteoporosis include antiresorptive agents and osteoanabolic agents. Some antiresorptive agents are bisphosphonates, estrogen, raloxifene and calcitonin (Vokes and Favus, 2010). The anti-resorptive agents reduce the fracture risk primarily by blocking bone resorption. Human parathyroid hormone (PTH 1-34, Teriparatide) is the only available anabolic agent in clinical use for the treatment of osteoporosis currently in the United States and available throughout most of the world. Intact human PTH 1-84 has been approved in many European countries (Silva and Bilezikian, 2011). Intermittent administration of PTH

Address correspondence to: Marja M. Hurley, MD, Department of Medicine, University of Connecticut Health Center, 263 Farmington Ave., Farmington, CT, USA, 06030. Phone: 860-679-3483, FAX: 860-679-1875; hurley@nso1.uchc.edu.

peptide 1-34 or full-length protein PTH 1-84 increases bone formation in osteoporotic patients (Hodsman et al., 2005). The present article will focus on extracellular factors that mediate PTH bone anabolic effects.

Bone Biology

Bones can be thought of as an organ of the skeletal system. They provide mechanical support to soft tissues, and support muscle action and haematopoiesis. They also contribute to mineral homeostasis. These functions are accomplished by continuous bone remodeling which is coupled by bone resorption and bone formation (Harada and Rodan, 2003; Raisz, 2005). Bone resorption is carried out by osteoclasts, which are derived from hematopoietic lineage. Bone formation is carried out by osteoblasts, which are mesenchyme-derived. The bone resorption period is usually rapid within several days while the bone formation period is relatively slow over several months. The complete remodeling cycle takes about 3–6 months (Baron, 2003).

Osteoblasts differentiation

Osteoblasts originate from mesenchymal stem cells. Differentiation of mesenchymal stem cells towards osteoblasts is governed by a series of transcription factors, including runt-related transcription factor 2 (Runx2), osterix and activating transcription factor 4 (ATF4) (Franceschi et al., 2007; Karsenty, 2008), Figure 1. Mature osteoblasts will lay down bone matrix proteins including type I collagen and osteocalcin, which will slowly mineralize. Therefore, type I collagen is considered as an early stage of osteoblasts marker. Mature osteoblasts secrete osteocalcin, which is considered to be a late stage of osteoblasts marker. As cells differentiate, while the majority of osteoblasts die, some osteoblasts become osteocytes embedding in bone matrix and some become bone-lining cells (Baron, 2003).

Osteoclast differentiation

Osteoclasts originate from hematopoietic stem cells and osteoclasts differentiation is regulated by osteoblasts. The factors coupling osteoblasts to osteoclasts include macrophage colony-stimulating factor (M-CSF), the ligand for receptor activator of nuclear factor kappa B (RANKL) and osteoprotegerin (OPG) (Baron, 2003). Bone marrow stromal cells and osteoblasts express M-CSF as well as RANKL. M-CSF stimulates proliferation and differentiation of osteoclast progenitors. RANKL binding to receptor RANK on osteoclast progenitor surface is required for osteoclast differentiation. In addition to RANKL, osteoblasts also secrete OPG, which is a decoy receptor for RANKL and thus a negative regulator for osteoclast differentiation. Therefore, osteoclast maturation is regulated by osteoblasts (Baron, 2003).

Bone-remodeling process is well controlled by coordination of osteoblasts, osteoclasts, osteocytes, bone lining cells and other cells. Unbalanced bone remodeling, such as increased bone resorption and/or inadequate bone formation will result in bone loss. Inadequate bone formation might be due to alternations of commitment, proliferation and differentiation of osteoblasts progenitors, as well as the lifespan of the mature osteoblasts.

Intermittent administration of PTH increases bone formation

The principal form of biological active parathyroid hormone is the intact molecule, PTH (1-84). The amino-terminal (N) fragment, PTH (1-34) has similar biological activity to the full-length parathyroid hormone, PTH (1-84) (Hock et al., 2002). Intact human PTH 1-84 has been approved for therapeutic use in Canada and Europe but not in the United States. Currently teriparatide human PTH (1-34) is the only available anabolic agent in clinical use for the treatment of osteoporosis in the United States and most countries throughout the

world. Intermittent administration of PTH peptide 1-34 or full-length protein PTH 1-84 increases bone formation in osteoporotic patients (Hodsman et al., 2005).

In osteoblast, PTH signals through receptor PTH1R and PTH can stimulate extracellular calcium influx through cAMP-dependent and cAMP-independent pathway or PKC signaling pathway (Hock et al., 2002; Swarthout et al., 2002). Although no PTH receptors were found on osteoclasts, PTH can regulate osteoclast indirectly through osteoblasts. Continuous PTH treatment has been demonstrated to increase RANKL expression and down regulate expression of OPG, thereby favoring osteoclastogenesis and bone resorption (Hock et al., 2002). However, intermittent administration of PTH in vivo has been well documented to increase bone formation (Hock et al., 2002).

PTH intermittent administration stimulates bone formation as well as bone resorption. However, there is a period when PTH enhances bone formation to a greater extent than PTH stimulates bone resorption (Canalis et al., 2007). The period is considered as “the anabolic window”. Considering that the bone anabolic effects of PTH wane after the anabolic window and that long-term effects of PTH administration has not been evaluated, the recommended duration of PTH therapy is relatively short: 2 years in the United States and 18 months in Europe (Canalis et al., 2007). During the anabolic window, it is known that bone formation markers increase before bone resorption markers. Other morphometric observations including bone volume, bone microstructure and mechanical properties also confirmed the anabolic effects of PTH on bone (Canalis et al., 2007).

Intermittent PTH treatment has been demonstrated to increase bone formation by acting on different phases of bone remodeling (Figure 2): stimulating precursors commitment into osteoblasts lineage, promoting osteoblast differentiation, inhibiting osteoblast apoptosis and inhibiting proliferation of osteoblast progenitors (Jilka, 2007). Intermittent PTH treatment increased osteoblasts number also by attenuating progenitors differentiation into adipocytes and by reactivating bone lining cells (Jilka, 2007). In addition, PTH stimulates bone resorption, which release factors important for bone formation (Jilka, 2007). Besides bone cells, bone marrow microenvironment has been recently shown to impact anabolic actions of PTH (Koh et al., 2011). Since the FDA approved intermittent PTH administration in 2002, great progress has been made in understanding how intermittent PTH treatment mediates its bone anabolic effects. However, the detailed mechanisms are still not fully defined.

Our studies suggest that PTH increasing of osteoblasts number and promoting osteoblasts differentiation is partially mediated by extracellular factors, including fibroblast growth factor 2 (FGF2) and Wnt proteins (Figure 3).

Anabolic actions of PTH on bone require FGF2

FGF2 is one of the earliest members identified in the FGF polypeptide family (Hurley et al., 2002). It is expressed in osteoblasts and stored in extracellular matrix (Hurley et al., 2002). The clinical importance of FGF2 in bone has been revealed in recent studies. We observed that FGF2 expression decreased in osteoblasts from aged patients compared to young patients (unpublished data). However, PTH intermittent treatment increased serum FGF2 in osteoporotic patients (Hurley et al., 2005). In addition, FGF2 stimulates proliferation of mesenchymal-derived progenitor cells from aging mouse and human bone (Ou et al., 2010). Furthermore, FGF2 has been used in clinical trials to stimulate periodontal regeneration (Kitamura et al., 2011) and to accelerate healing of tibial shaft fractures (Kawaguchi et al., 2010). Additionally, polymorphisms of the FGF2 gene may contribute to the susceptibility of osteoporosis (Lei et al., 2011). These studies indicate the clinical relevance of FGF2 research.

FGF2 signals through FGF receptors that have tyrosine kinase activity (Powers et al., 2000). Binding of FGF2 to FGF receptors induces receptor dimerization and activation, resulting in activation of downstream signaling. FGF2 downstream signaling pathways include mitogen-activated-protein kinase (MAPK) pathway, the PI-3 kinase-AKT pathway and the phospholipase C (PLC) pathway (Dailey et al., 2005). MAPK pathways with extracellular signal-regulated kinases (Erks), P38 MAP kinases and protein kinase C (PKC) are well studied in osteoblasts (Marie, 2003).

Although sustained FGF2 treatment maintains the osteoblast precursor proliferative state thereby reducing osteoblasts differentiation and inhibiting bone formation (Canalis et al., 1988; Hurley et al., 1993; Rodan et al., 1989), osteoblast precursors are able to differentiate in the absence of continuous FGF2 exposure. Intermittent FGF2 treatment increases osteoblasts differentiation and bone formation (Mayahara et al., 1993; Nakamura et al., 1998). The increased bone formation induced by intermittent FGF2 may also be partially due to enhanced osteoblasts replication (Globus et al., 1988; Ou et al., 2010). This is reminiscent of the actions of PTH where continuous treatment inhibits osteoblast differentiation and new bone formation, whereas intermittent PTH increases bone formation.

The importance of FGF2 in bone is supported by our studies using FGF2 null mice. Disruption of the *Fgf2* gene results in significantly decreased bone mass and bone formation revealed by histomorphometry and micro-CT data (Montero et al., 2000). Furthermore, FGF2 knockout mice display greatly reduced trabecular plate-like structures and loss of connecting rods (Montero et al., 2000). This decreased bone formation phenotype might not be due to reduced progenitors as both wild type and FGF2 knockout BMSCs have similar colony forming efficiency (Xiao et al., 2010). Instead, this decreased bone formation phenotype may be due to alteration of progenitor cell lineage commitment, since FGF2 deficiency results in increased bone marrow adipogenesis and reduced osteogenesis (Xiao et al., 2010). The reduced bone formation may be also due to a defect in osteoblast differentiation as shown by decreased alkaline phosphatase (ALP) positive colonies and von Kossa staining in cultured *Fgf2*^{-/-} BMSCs (Montero et al., 2000). The decreased colony area can be partially rescued by exogenous FGF2 administration to *Fgf2*^{-/-} BMSCs *in vitro* (Montero et al., 2000; Naganawa, et al., 2006). FGF2 could also stimulate bone formation *in vivo* (Mayahara et al., 1993; Nakamura et al., 1998). These studies show that FGF2 is a positive regulator of osteoblast differentiation and bone formation.

In addition to the function in osteoblasts differentiation and bone formation, FGF2 is also required for osteoclast formation and bone resorption since FGF2 deletion results in reduced osteoclast formation and resorption both *in vitro* (Okada et al., 2003) and *in vivo* (Montero et al., 2000). FGF2 also negatively regulate adipogenesis as FGF2 deletion results in increased adipogenesis in bone marrow but exogenous FGF2 treatment block adipogenesis in BMSCs (Xiao et al., 2010). Therefore, similar to PTH, FGF2 stimulates bone formation also by regulating function of osteoclasts and adipocytes.

Interestingly, other factors important for bone homeostasis also regulate FGF2 expression in osteoblasts, for example: prostaglandins (Sabbieti et al., 1999), transforming growth factor β (Hurley et al., 1994), bone morphogenetic protein-2 (Naganawa et al., 2008), 17 β -estradiol (Hurley et al., 1996) and PTH (Hurley et al., 1999; Hurley et al., 2005) all increase FGF2 mRNA and protein.

We previously demonstrated that PTH increases FGF2 and FGF receptor mRNA expression in cultured osteoblasts (Hurley et al., 1999). The mechanisms by which PTH regulates FGF2 involve protein kinase A (PKA)-cAMP and/or PKC pathway activation, since activators for PKA and PKC pathway all increased FGF2 expression, which mimicked the stimulatory

effect of PTH on FGF2 expression (Hurley MM, 1999). Ongoing studies are further characterizing how PTH regulates FGF2. Besides increasing FGF2 in mouse cells, PTH treatment increases serum FGF2 and increases bone formation markers in osteoporotic patients (Hurley et al., 2005). The increased bone formation markers including osteocalcin (OCN) may be partially due to increased FGF2 because FGF2 was shown to induce OCN mRNA expression in cultured osteoblasts (Xiao et al., 2002). FGF2 stimulation of new bone formation *in vivo* is also well documented (Mayahara et al., 1993). However, disruption of FGF2 gene in mice results in dramatic reduction in bone formation and OCN expression (Naganawa, et al., 2006). Moreover, in *Fgf2*^{-/-} mice, the anabolic action of PTH in bone is greatly impaired. PTH treatment significantly increased bone formation in FGF2 wild type mice but the increase was blunted in *Fgf2*^{-/-} mice (Hurley et al., 2006). PTH promoted bone formation by increasing expression of osteoblasts differentiation transcription factor Runx2 and of proteins involved in osteoblasts proliferation and viability, but the increase was greatly attenuated by FGF2 deficiency (Sabbieti et al., 2009). *Therefore, anabolic effects of PTH on bone formation require endogenous FGF2.* However, the downstream target of FGF2 signaling is not well understood.

The impaired anabolic effect of PTH in *Fgf2*^{-/-} mice is in part due to reduced ATF4 expression

Recent studies identify transcription factor ATF4 as a novel downstream target gene of PTH signaling in osteoblasts (Yu et al., 2008). ATF4 is a transcription factor important for osteoblasts terminal differentiation and mineralization (Yang et al., 2004). PTH induces ATF4 mRNA/protein expression in a time and dose dependent manner. In addition, PTH increases ATF4 transcriptional activity in MC-4 cells and in BMSCs (Yu et al., 2008). PTH increases expression of OCN mRNA and protein in a time and dose dependent manner in cultured osteoblasts (Jiang et al., 2004; Yu et al., 2008). However, PTH could not induce OCN expression in ATF4 knockdown MC-4 cells or in *Atf4*^{-/-} BMSCs (Yu, et al., 2008). Moreover, PTH stimulated bone formation was significantly reduced or lost in *Atf4*^{-/-} mice (Yu et al., 2009). These results indicate that *the transcription factor ATF4 mediates the anabolic actions of PTH in bone.*

Expression of transcription factor ATF4 is regulated by FGF2 in osteoblasts, as shown in our recent paper (Fei et al., 2010). We studied the ability of FGF2 to increase expression of ATF4 in BMSCs and examined ATF4 expression in FGF2 deficient BMSCs. We observed that FGF2 increased ATF4 mRNA expression as early as 20min and stimulated ATF4 protein expression after 3 hours of treatment in BMSCs. In addition, ATF4 expression was markedly reduced in cultured BMSCs from *Fgf2*^{-/-} mice compared to wild type mice. We further showed that exogenous FGF2 increased ATF4 expression in *Fgf2*^{-/-} BMSCs as well as in *Fgf2*^{+/+} BMSCs. These results suggest that impaired bone mass and bone formation in *Fgf2* null mice may be due in part to reduced ATF4 expression and that anabolic bone action of FGF2 is partially mediated by ATF4.

Further, we showed that the impaired anabolic effect of PTH in *Fgf2*^{-/-} mice is in part due to reduced ATF4 expression both *in vitro* and *in vivo* (Fei et al., 2011b). *In vitro* data showed that PTH treatment increased ATF4 mRNA expression as early as 15 min in *Fgf2*^{+/+} BMSCs, but no significant increase was observed in *Fgf2*^{-/-} BMSCs. *In vivo* data showed that there was a 13.8% increase in lumbar vertebrae bone mineral density in *Fgf2*^{+/+} mice after 2 weeks intermittent treatment with PTH (1-34) (40ug/kg/d). In contrast, there was a 2.1% decrease in FGF2 deficient mice after PTH intermittent treatment. Consistent with increased bone formation, PTH treatment also enhanced expression of genes that are important for osteoblasts differentiation including type I collagen, osteocalcin and Runx2. However, the increase was attenuated in FGF2 deficient mice. Interestingly, basal

expression of ATF4 mRNA in tibiae was significantly lower in *Fgf2* null mice compared to wild type mice. PTH treatment significantly increased ATF4 mRNA in *Fgf2* wild type mice, but there was no significant increase in *Fgf2* null mice. In addition, ATF4 protein expression measured by immunohistochemistry on lumbar vertebrae tissue was increased by PTH treatment in *Fgf2*^{+/+} mice but the increase was attenuated in *Fgf2*^{-/-} mice. The attenuated ATF4 expression might reduce osteoblasts differentiation, and possibly contributes to the impaired anabolic action of PTH on bone formation in *Fgf2*^{-/-} mice. One needs to note that the impaired PTH bone response in FGF2 deficient mice on a new genetic background of black swiss/129/FVB/N (Fei et al., 2011b), although with lower dosage of PTH, is consistent with the data reported in mice on a black swiss/129Sv genetic background (Hurley et al., 2006). These data further support that *maximal anabolic actions of PTH in bone require FGF2 signaling, which might be mediated by transcription factor ATF4.*

Building bone by PTH/Wnt signaling

Wnt signaling pathway also mediates anabolic action of PTH on bone. Wnt signaling is particularly important for bone homeostasis. Wnt can either signal through non-canonical pathway or the canonical Wnt/ β -catenin pathway. The non-canonical β -catenin independent pathway includes Wnt/Calcium pathway and Wnt/planar cell polarity pathway (Peters et al., 2008). The canonical Wnt/ β -catenin pathway is well studied in osteoblasts. In the absence of Wnt ligand, the destruction complex including kinase GSK3 β will degrade the key signaling factor β -catenin. In order to initiate the signaling cascade, Wnt ligand binds to receptor LRP5/LRP6 and Frizzled. This binding will block the destruction complex, therefore, β -catenin will be stabilized and accumulate in the nucleus. Nucleus β -catenin binds to transcription factor Lymphoid enhancer-binding factor 1/T cell specific transcription factor (LEF/TCF) and activate expression of downstream target genes such as Runx2 to promote osteoblasts differentiation (Peters et al., 2008). The importance of Wnt signaling pathway is well demonstrated in human mutations. Patients with loss of function mutations in the receptors LRP5 (Gong et al., 2001) or LRP6 (Mani et al., 2007) are characterized with low bone mineral density and skeletal fragility. In contrast, patients with gain of function mutations in LRP5 (reduced affinity of LRP5 for Dkk1) have high bone mass (Ai et al., 2005; Boyden et al., 2002; Van Wesenbeeck et al., 2003).

Wnt/ β -Catenin signaling regulating osteoblasts differentiation and bone formation involves multiple mechanisms. Wnt/ β -Catenin signaling stimulates progenitors commitment into osteoblasts lineage and attenuates progenitors differentiation into adipocytes. Wnt/ β -Catenin signaling also promotes osteoblasts proliferation, differentiation and mineralization. In addition, Wnt/ β -Catenin signaling represses osteoclasts differentiation by increasing the ratio of OPG/RANKL (Krishnan et al., 2006). Thus, Wnt/ β -Catenin signaling stimulation of bone formation is through multiple mechanisms, which is common in the anabolic effects of PTH as well as of FGF2 in bone.

The function of Wnt/ β -Catenin signaling on bone formation is negatively regulated by Wnt antagonists including sclerostin (Kamiya et al., 2008), dickkopf (Dkks) (Kawano and Kypta, 2003), and secreted frizzled related proteins (sFRPs) (Bodine et al., 2004; Yao et al., 2010). Sclerostin and DKKs block Wnt/ β -Catenin signaling by binding to one subunit of the Wnt receptor complex. In contrast, sFRPs bind to Wnt proteins and inactivate all Wnt pathway (Kawano and Kypta, 2003). Dkk1 has been demonstrated to antagonize canonical Wnt signaling and inversely correlates with bone mass (Li et al., 2006; MacDonald et al., 2007; Mao et al., 2001; Morvan et al., 2006). Sclerostin (Brunkow et al., 2001; Li et al., 2008; Li et al., 2009), sFRP1 (Bodine et al., 2004; Yao et al., 2010) and sFRP4 (Cho et al., 2010; Nakanishi et al., 2008; Nakanishi et al., 2006) also negatively regulate bone mass.

Wnt Signaling pathway also mediates the anabolic action of PTH on bone. Micro-array analysis revealed that both *in vitro* and *in vivo* PTH treatment regulates genes of the Wnt signaling family (Kulkarni et al., 2005; Li et al., 2007; Onyia et al., 2005; Qin et al., 2003). PTH treatment increased the key factor of Wnt signaling β -catenin in a dose and time dependent manner (Tobimatsu et al., 2006; Wan et al., 2008). In addition, PTH treatment significantly increased nuclear localized β -catenin protein in a fracture repair model (Kakar et al., 2007). However, knocking down β -catenin using siRNA blunted the increase of genes important for osteoblast differentiation Runx2, OCN, ALP by PTH treatment (Tian et al., 2011). The mechanisms by which PTH stimulation of β -catenin involves PKA and PKC pathways since activators of PKA and PKC pathway all increased β -catenin expression, however, the specific inhibitors of PKA and PKC pathway antagonized PTH induction of β -catenin levels (Tobimatsu et al., 2006). PTH stimulation of β -catenin levels was also mediated by Smad3 (Inoue et al., 2009; Tobimatsu et al., 2006). Another mechanism by which PTH facilitates β -catenin signaling is through inactivation of kinase GSK-3 β (Suzuki et al., 2008). These data support that the Wnt signaling key factor pathway β -catenin mediates bone anabolic effect of PTH.

Furthermore, recent data show that PTH receptor PTH1R interacts with Wnt co-receptor Lrp6, thereby activating Wnt/ β -catenin signaling (Wan et al., 2008). PTH1R can also regulate Wnt/ β -catenin signaling independent of Lrp6. Another Wnt co-receptor is frizzled and frizzled requires adaptor protein dishevelled to activate Wnt/ β -catenin signaling. It has been shown that PTH1R can directly interact with dishevelled, independent of Lrp6, to regulate β -catenin signaling (Romero et al., 2010).

PTH activation of Wnt/ β -catenin signaling not only stimulates osteoblasts differentiation and bone formation (Tobimatsu et al., 2006; Wan et al., 2008) but also induces osteoclastogenesis (Romero et al., 2010).

Besides canonical Wnt/ β -catenin signaling, PTH has also been demonstrated to activate non-canonical Wnt signaling in bone. PTH treatment stimulates expression of non-canonical Wnt ligand Wnt 4 in osteoblasts and this stimulation is primarily through PKA pathway (Bergensstock and Partridge, 2007; Li et al., 2007).

In addition to direct regulation of Wnt signaling in bone by PTH, PTH also regulates Wnt signaling indirectly through Wnt antagonists. As described above, Wnt antagonist sclerostin negatively regulates Wnt signaling pathway. *Sost* is the gene that encodes protein sclerostin and sclerostin is mainly expressed by osteocytes (van Bezooijen et al., 2004; Winkler et al., 2003). Sclerostin has been reported to bind to receptor LRP5/6 (Li et al., 2005; ten Dijke et al., 2008), thereby antagonizing β -Catenin signaling and negatively regulating bone formation. Patients with sclerostin deficiency in sclerosteosis or Van Buchem disease display tremendous increase in bone mass and BMD throughout the skeleton (Van Hul et al., 1998). Similarly, mice deficient of *Sost* exhibit a high bone mass phenotype (Kramer et al., 2010; Li, et al., 2008), in contrast, mice overexpressing sclerostin display a low bone mass phenotype (Kramer et al., 2010; Loots et al., 2005; Winkler et al., 2003). These studies confirmed the negative regulation of sclerostin in bone. Recently, sclerostin was shown to be involved in the anabolic bone effect of PTH. Patient studies showed that serum sclerostin levels negatively correlate with PTH levels (Ardawi et al., 2011; Mirza et al., 2010) and intermittent PTH therapy in patients reduced circulating sclerostin levels (Drake et al., 2010). Animal studies confirm that sclerostin is a target for PTH in bone. PTH treatment induced a dramatic reduction of *Sost* mRNA and sclerostin *in vitro* as well as *in vivo* (Bellido et al., 2005; Keller and Kneissel, 2005). Furthermore, intermittent PTH treatment induced bone gain is blunted in *SOST* overexpression and deficient mice due to attenuated

bone formation (Kramer et al., 2010). These data indicates that PTH anabolic effects involve suppression of sclerostin, an inhibitor of bone formation.

The studies discussed above suggest that sclerostin might be a promising target to induce bone formation. Indeed, using sclerostin antibody to enhance bone formation has been under intense study. Blocking the endogenous inhibitor sclerostin using antibody will lead to activation of canonical Wnt signaling, which will stimulate bone formation. Sclerostin antibody treatment has been reported to enhance bone formation in aged osteoporotic animals (Agholme et al., 2010; Li, et al., 2009) as well as in young animals Agholme et al., 2010). In addition, sclerostin antibody treatment enhances bone formation not only in loss of bone (osteoporotic) setting (Li, et al., 2009), it also enhances fracture healing and strengthens bone density and strength of non-fractured bones. Ominsky et al., 2011). Importantly, increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or co-treatment with anti-resorptive drugs (Li et al., 2011). All these data indicate that sclerostin antibody is a promising agent for the treatment of osteoporosis or to enhance fracture healing in patients.

Notably, PTH is still able to increase bone formation in the absence of sclerostin (Kramer et al., 2010), supporting that other factors such as FGF2 (Fei et al., 2011b; Hurley et al., 2006), ATF4 (Yu et al., 2009) and other Wnt signaling regulators also play important roles in PTH bone anabolic effects.

Another Wnt antagonist DKK1 negatively regulates Wnt/ β -Catenin signaling by binding and antagonizing receptor LRP5/6 (He et al., 2004). DKK1 has been demonstrated to be a down-regulator of bone formation: deletion of a single allele of the *DKK1* gene in mice results in increased bone formation (Morvan et al., 2006); in contrast, overexpression of DKK1 inhibits Wnt/ β -Catenin signaling in bone and leads to osteopenia (Li et al., 2006). In addition, serum DKK1 levels was significantly increased in postmenopausal osteoporotic patients (Anastasilakis et al., 2010). Moreover, DKK1 neutralization antibody has been reported to protect from systemic bone loss during inflammation (Heiland et al., 2010) and induce bone formation in young growing animals as well as in traumatic injury models (Li et al., 2011). These data suggest that DKK1 negatively regulates bone formation and DKK1 antibody is a promising agent to increase bone formation in certain conditions. The role of DKK1 antagonizing Wnt/ β -Catenin signaling is also important in the bone effect of PTH. Suppression of Wnt signaling by Dkk1 attenuates PTH-mediated stromal cell response and new bone formation (Guo et al., 2010). Interestingly, targeted overexpression of Dkk1 in osteoblasts reduces bone mass but does not impair the anabolic response to intermittent PTH treatment in mice (Yao, et al., 2011). Therefore, further studies are needed to examine the role of DKK1 in the bone effect of PTH.

In addition, Wnt antagonist sFRP1 is also involved in PTH bone anabolic effects. sFRP1 is one member of sFRP family and sFRPs antagonize Wnt signaling by binding to Wnt ligands and preventing Wnt/receptor activation (Bovolenta et al., 2008). sFRP1 has been shown to be a negative regulator for bone formation: sFRP1 overexpression inhibits bone formation (Yao et al., 2010) and sFRP1 deficiency enhanced trabecular bone formation in mice (Bodine et al., 2004). Interestingly, decreased sFRP1 expression was associated with increased bone formation in low molecular mass FGF2 transgenic mice; in contrast, increased sFRP1 expression was associated with reduced bone formation in low molecular mass FGF2 knock out mice (Xiao et al., 2009). These data indicate that sFRP1 is a target of FGF2 signaling and future studies will determine the detailed mechanism by which FGF2 regulates sFRP1. Additionally, sFRP1 inhibitor has been reported to stimulate bone formation (Bodine et al., 2009). Consistent with the negative bone formation regulatory role of sFRP1, sFRP1 overexpression attenuates PTH bone anabolic effects. On the other hand,

bone anabolic effects of PTH are blunted in the absence of sFRP1 (Bodine et al., 2007). These data suggest that maximal PTH anabolic for bone requires a certain amount of sFRP1.

Summary and future directions

Overall, this article summarizes the role of extracellular signals of FGF2 and Wnt signaling in PTH bone anabolic effects. As one of the very few potent anabolic agents for osteoporosis, PTH increases osteoblasts number, stimulates osteoblasts differentiation and bone formation through multiple ways (Figure 2). This PTH bone anabolic effect is mediated by extracellular factors. Maximal bone anabolic effect of PTH requires FGF2 signaling, which might be mediated by transcription factor ATF4. Maximal bone anabolic effect of PTH also requires Wnt signaling. Particularly, Wnt antagonists such as sclerostin, DKK1 and sFRP1 are promising targets to increase bone formation. Interestingly, we recently demonstrated that FGF2 stimulation of bone formation is modulated by Wnt/ β -Catenin signaling (Fei et al., 2011a) (Figure 3). Therefore, the multiple signaling pathways utilized by PTH are cross talking and working together to promote bone formation. Extensive studies on the mechanisms of action of PTH will help to identify new pathways that regulate bone formation, to improve available agents to stimulate bone formation, and to identify potential new anabolic agents for osteoporosis.

Acknowledgments

Contract grant sponsor: NATIONAL INSTITUTE ON AGING;

Contract grant number: 5R01AG021189.

References

- Agholme F, Li X, Isaksson H, Ke HZ, Aspenberg P. Sclerostin antibody treatment enhances metaphyseal bone healing in rats. *J Bone Miner Res*. 2010; 25(11):2412–2418. [PubMed: 20499342]
- Ai M, Holmen SL, Van Hul W, Williams BO, Warman ML. Reduced Affinity to and Inhibition by DKK1 Form a Common Mechanism by Which High Bone Mass-Associated Missense Mutations in LRP5 Affect Canonical Wnt Signaling. *Mol Cell Biol*. 2005; 25(12):4946–4955. [PubMed: 15923613]
- Anastasilakis AD, Polyzos SA, Avramidis A, Toulis KA, Papatheodorou A, Terpos E. The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis. *Clin Endocrinol (Oxf)*. 2010; 72(6):752–757. [PubMed: 19832854]
- Ardawi MS, Al-Sibiany AM, Bakhsh TM, Rouzi AA, Qari MH. Decreased serum sclerostin levels in patients with primary hyperparathyroidism: a cross-sectional and a longitudinal study. *Osteoporos Int* [Epub ahead of print]. 2011
- Baron, R. General Principles of Bone Biology. In: Favus, MJ., editor. *Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism*. Washington, DC: the American Society for Bone and Mineral Research; 2003. p. 1-8.
- Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O'Brien CA, Manolagas SC, Jilka RL. Chronic Elevation of Parathyroid Hormone in Mice Reduces Expression of Sclerostin by Osteocytes: A Novel Mechanism for Hormonal Control of Osteoblastogenesis. *Endocrinology*. 2005; 146(11): 4577–4583. [PubMed: 16081646]
- Bergenstock MK, Partridge NC. Parathyroid hormone stimulation of noncanonical Wnt signaling in bone. *Ann N Y Acad Sci*. 2007; 1116:354–359. [PubMed: 18083937]
- Bodine PV, Seestaller-Wehr L, Kharode YP, Bex FJ, Komm BS. Bone anabolic effects of parathyroid hormone are blunted by deletion of the Wnt antagonist secreted frizzled-related protein-1. *J Cell Physiol*. 2007; 210(2):352–357. [PubMed: 17044082]

- Bodine PV, Zhao W, Kharode YP, Bex FJ, Lambert AJ, Goad MB, Gaur T, Stein GS, Lian JB, Komm BS. The Wnt Antagonist Secreted Frizzled-Related Protein-1 Is a Negative Regulator of Trabecular Bone Formation in Adult Mice. *Mol Endocrinol*. 2004; 18(5):1222–1237. [PubMed: 14976225]
- Bodine PVN, Stauffer B, Ponce-de-Leon H, Bhat RA, Mangine A, Seestaller-Wehr LM, Moran RA, Billiard J, Fukayama S, Komm BS, Pitts K, Krishnamurthy G, Gopalsamy A, Shi M, Kern JC, Commons TJ, Woodworth RP, Wilson MA, Welmaker GS, Trybulski EJ, Moore WJ. A small molecule inhibitor of the Wnt antagonist secreted frizzled-related protein-1 stimulates bone formation. *Bone*. 2009; 44(6):1063–1068. [PubMed: 19254787]
- Bovolenta P, Esteve P, Ruiz JM, Cisneros E, Lopez-Rios J. Beyond Wnt inhibition: new functions of secreted Frizzled-related proteins in development and disease. *J Cell Sci*. 2008; 121(6):737–746. [PubMed: 18322270]
- Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, Wu D, Insogna K, Lifton RP. High bone density due to a mutation in LDL-receptor-related protein 5. *N Engl J Med*. 2002; 346(20):1513–1521. [PubMed: 12015390]
- Brunkow ME, Gardner JC, Van Ness J, Paepers BW, Kovacevich BR, Proll S, Skonier JE, Zhao L, Sabo PJ, Fu Y-H, Alisch RS, Gillett L, Colbert T, Tacconi P, Galas D, Hamersma H, Beighton P, Mulligan JT. Bone Dysplasia Sclerosteosis Results from Loss of the SOST Gene Product, a Novel Cystine Knot-Containing Protein. *Am J Hum Genet*. 2001; 68(3):577–589. [PubMed: 11179006]
- Canalis E, Centrella M, McCarthy T. Effects of basic fibroblast growth factor on bone formation in vitro. *J Clin Invest*. 1988; 81(5):1572–1577. [PubMed: 3366907]
- Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. *N Engl J Med*. 2007; 357(9):905–916. [PubMed: 17761594]
- Cho HY, Choi HJ, Sun HJ, Yang JY, An JH, Cho SW, Kim SW, Kim SY, Kim JE, Shin CS. Transgenic mice overexpressing secreted frizzled-related proteins(sFRP)4 under the control of serum amyloid P promoter exhibit low bone mass but did not result in disturbed phosphate homeostasis. *Bone*. 2010; 47(2):263–271. [PubMed: 20472109]
- Dailey L, Ambrosetti D, Mansukhani A, Basilico C. Mechanisms underlying differential responses to FGF signaling. *Cytokine Growth Factor Rev*. 2005; 16(2):233–247. [PubMed: 15863038]
- Drake MT, Srinivasan B, Modder UI, Peterson JM, McCready LK, Riggs BL, Dwyer D, Stolina M, Kostenuik P, Khosla S. Effects of Parathyroid Hormone Treatment on Circulating Sclerostin Levels in Postmenopausal Women. *J Clin Endocrinol Metab*. 2010; 95(11):5056–5062. [PubMed: 20631014]
- Fei Y, Xiao L, Doetschman T, Coffin DJ, Hurley MM. Fibroblast Growth Factor 2 Stimulation of Osteoblast Differentiation and Bone Formation Is Mediated by Modulation of the Wnt Signaling Pathway. *J Biol Chem*. 2011a; 286(47):40575–40583. [PubMed: 21987573]
- Fei Y, Xiao L, Hurley MM. The impaired bone anabolic effect of PTH in the absence of endogenous FGF2 is partially due to reduced ATF4 expression. *Biochem Biophys Res Commun*. 2011b; 412(1):160–164. [PubMed: 21806973]
- Fei Y, Xiao L, Hurley MM. Fibroblast growth factor 2 positively regulates expression of activating transcription factor 4 in osteoblasts. *Biochem Biophys Res Commun*. 2010; 391(1):335–339. [PubMed: 19913500]
- Franceschi RT, Ge C, Xiao G, Roca H, Jiang D. Transcriptional regulation of osteoblasts. *Ann N Y Acad Sci*. 2007; 1116:196–207. [PubMed: 18083928]
- Globus RK, Patterson-Buckendahl P, Gospodarowicz D. Regulation of Bovine Bone Cell Proliferation by Fibroblast Growth Factor and Transforming Growth Factor β . *Endocrinology*. 1988; 123(1):98–105. [PubMed: 2838270]
- Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM, Wang H, Cundy T, Glorieux FH, Lev D, Zacharin M, Oexle K, Marcelino J, Suwairi W, Heeger S, Sabatakis G, Apte S, Adkins WN, Allgrove J, Arslan-Kirchner M, Batch JA, Beighton P, Black GCM, Boles RG, Boon LM, Borrone C, Brunner HG, Carle GF, Dallapiccola B, De Paepe A, Floege B, Halfhide ML, Hall B, Hennekam RC, Hirose T, Jans A, Jüppner H, Kim CA, Kepler-Noreuil K, Kohlschütter A, LaCombe D, Lambert M, Lemire E, Letteboer T, Peltonen L, Ramesar RS, Romanengo M, Somer H, Steichen-Gersdorf E, Steinmann B, Sullivan B, Superti-Furga A, Swoboda W, van den Boogaard MJ, Van Hul W, Vikkula M, Votruba M, Zabel B, Garcia T, Baron R, Olsen BR,

- Warman ML. LDL Receptor-Related Protein 5 (LRP5) Affects Bone Accrual and Eye Development. *Cell*. 2001; 107(4):513–523. [PubMed: 11719191]
- Guo J, Liu M, Yang D, Bouxsein ML, Saito H, Galvin RJ, Kuhstoss SA, Thomas CC, Schipani E, Baron R, Bringham FR, Kronenberg HM. Suppression of Wnt Signaling by Dkk1 Attenuates PTH-Mediated Stromal Cell Response and New Bone Formation. *Cell Metabolism*. 2010; 11(2): 161–171. [PubMed: 20142103]
- Harada, S-i; Rodan, GA. Control of osteoblast function and regulation of bone mass. *Nature*. 2003; 423(6937):349–355. [PubMed: 12748654]
- He X, Semenov M, Tamai K, Zeng X. LDL receptor-related proteins 5 and 6 in Wnt/ β -catenin signaling: Arrows point the way. *Development*. 2004; 131(8):1663–1677. [PubMed: 15084453]
- Heiland GR, Zwerina K, Baum W, Kireva T, Distler H Jr, Grisanti M, Asuncion F, Li X, Ominsky M, Richards W, Schett G, Zwerina J. Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression. *Ann Rheum Dis*. 2010; 69(12):2152–2159. [PubMed: 20858621]
- Hock, JM.; Fitzpatrick, LA.; Bilezikian, JP. Actions of Parathyroid Hormone. In: Bilezikian, JP.; Raisz, LG.; Rodan, G., editors. *Principles of bone biology*. San Diego: Academic Press; 2002. p. 463–481.
- Hodsman AB, Bauer DC, Dempster DW, Dian L, Hanley DA, Harris ST, Kendler DL, McClung MR, Miller PD, Olszynski WP, Orwoll E, Yuen CK. Parathyroid Hormone and Teriparatide for the Treatment of Osteoporosis: A Review of the Evidence and Suggested Guidelines for Its Use. *Endocr Rev*. 2005; 26(5):688–703. [PubMed: 15769903]
- Holroyd C, Cooper C, Dennison E. Epidemiology of osteoporosis. *Best Pract Res Clin Endocrinol Metab*. 2008; 22(5):671–685. [PubMed: 19028351]
- Hurley MM, Abreu C, Gronowicz G, Kawaguchi H, Lorenzo J. Expression and regulation of basic fibroblast growth factor mRNA levels in mouse osteoblastic MC3T3-E1 cells. *J Biol Chem*. 1994; 269(12):9392–9396. [PubMed: 8132679]
- Hurley MM, Abreu C, Harrison JR, Lichtler AC, Raisz LG, Kream BE. Basic fibroblast growth factor inhibits type I collagen gene expression in osteoblastic MC3T3-E1 cells. *J Biol Chem*. 1993; 268(8):5588–5593. [PubMed: 8449921]
- Hurley MM, Abreu C, Marcello K, Gronowicz G, Raisz LGJ. Translational regulation of the FGF2 gene by 17 β -Estradiol. *Bone*. 1996; 17(6) Abs.31a.
- Hurley MM, Okada Y, Xiao L, Tanaka Y, Ito M, Okimoto N, Nakamura T, Rosen CJ, Doetschman T, Coffin JD. Impaired bone anabolic response to parathyroid hormone in Fgf2 $^{-/-}$ and Fgf2 $^{+/-}$ mice. *Biochem Biophys Res Commun*. 2006; 341(4):989–994. [PubMed: 16455048]
- Hurley MM, Tetradis S, Huang YF, Hock J, Kream BE, Raisz LG, Sabbieti MG. Parathyroid hormone regulates the expression of fibroblast growth factor-2 mRNA and fibroblast growth factor receptor mRNA in osteoblastic cells. *J Bone Miner Res*. 1999; 14(5):776–783. [PubMed: 10320526]
- Hurley MM, Yao W, Lane NE. Changes in serum fibroblast growth factor 2 in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1–34). *Osteoporos Int*. 2005; 16(12):2080–2084. [PubMed: 16133640]
- Hurley, MM.; Marie, PJ.; Florkiewics, RZ. Fibroblast growth factor and fibroblast growth factor receptor families. In: Bilezikian, JP.; Raisz, LG.; Rodan, G., editors. *Principles of bone biology*. San Diego: Academic Press; 2002. p. 627–645.
- Inoue Y, Canaff L, Hendy GN, Hisa I, Sugimoto T, Chihara K, Kaji H. Role of Smad3, acting independently of transforming growth factor-beta, in the early induction of Wnt-beta-catenin signaling by parathyroid hormone in mouse osteoblastic cells. *J Cell Biochem*. 2009; 108(1):285–294. [PubMed: 19582775]
- Jiang D, Franceschi RT, Boules H, Xiao G. Parathyroid hormone induction of the osteocalcin gene. Requirement for an osteoblast-specific element 1 sequence in the promoter and involvement of multiple-signaling pathways. *J Biol Chem*. 2004; 279(7):5329–5337. [PubMed: 14634012]
- Jilka RL. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. *Bone*. 2007; 40(6):1434–1446. [PubMed: 17517365]
- Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. *Osteoporos Int*. 2006; 17(12):1726–1733. [PubMed: 16983459]

- Kamiya N, Ye L, Kobayashi T, Mochida Y, Yamauchi M, Kronenberg HM, Feng JQ, Mishina Y. BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway. *Development*. 2008; 135(22):3801–3811. [PubMed: 18927151]
- Kakar S, Einhorn TA, Vora S, Miara LJ, Hon G, Wigner NA, Toben D, Jacobsen KA, Al-Sebaei MO, Song M, Trackman PC, Morgan EF, Gerstenfeld LC, Barnes GL. Enhanced chondrogenesis and Wnt signaling in PTH-treated fractures. *J Bone Miner Res*. 2007; 22(12):1903–1912. [PubMed: 17680724]
- Karsenty G. Transcriptional control of skeletogenesis. *Annu Rev Genomics Hum Genet*. 2008; 9:183–196. [PubMed: 18767962]
- Kawaguchi H, Oka H, Jingushi S, Izumi T, Fukunaga M, Sato K, Matsushita T, Nakamura K. TESK Group. A local application of recombinant human fibroblast growth factor 2 for tibial shaft fractures: A randomized, placebo-controlled trial. *J Bone Miner Res*. 2010; 25(12):2459–2467.
- Kawano Y, Kypta R. Secreted antagonists of the Wnt signalling pathway. *J Cell Sci*. 2003; 116(13):2627–2634. [PubMed: 12775774]
- Keller H, Kneissel M. SOST is a target gene for PTH in bone. *Bone*. 2005; 37(2):148–158. [PubMed: 15946907]
- Kitamura M, Akamatsu M, Machigashira M, Hara Y, Sakagami R, Hirofujii T, Hamachi T, Maeda K, Yokota M, Kido J, Nagata T, Kurihara H, Takashiba S, Sibutani T, Fukuda M, Noguchi T, Yamazaki K, Yoshie H, Ioroi K, Arai T, Nakagawa T, Ito K, Oda S, Izumi Y, Ogata Y, Yamada S, Shimauchi H, Kunitatsu K, Kawanami M, Fujii T, Furuuchi Y, Furuuchi T, Sasano T, Imai E, Omae M, Watanuki M, Murakami S. FGF-2 Stimulates Periodontal Regeneration. *J Dent Res*. 2011; 90(1):35–40. [PubMed: 21059869]
- Koh AJ, Novince CM, Li X, Wang T, Taichman RS, McCauley LK. An Irradiation-Altered Bone Marrow Microenvironment Impacts Anabolic Actions of PTH. *Endocrinology*. 2011; 152(12):4525–4536. [PubMed: 22045660]
- Kramer I, Loots GG, Studer A, Keller H, Kneissel M. Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice. *J Bone Miner Res*. 2010; 25(2):178–189. [PubMed: 19594304]
- Krishnan V, Bryant HU, Macdougald OA. Regulation of bone mass by Wnt signaling. *J Clin Invest*. 2006; 116(5):1202–1209. [PubMed: 16670761]
- Kulkarni NH, Halladay DL, Miles RR, Gilbert LM, Frolik CA, Galvin RJ, Martin TJ, Gillespie MT, Onyia JE. Effects of parathyroid hormone on Wnt signaling pathway in bone. *J Cell Biochem*. 2005; 95(6):1178–1190. [PubMed: 15962290]
- Lei SF, Papasian CJ, Deng HW. Polymorphisms in predicted miRNA binding sites and osteoporosis. *J Bone Miner Res*. 2011; 26(1):72–78. [PubMed: 20641033]
- Li J, Sarosi I, Cattle RC, Pretorius J, Asuncion F, Grisanti M, Morony S, Adamu S, Geng Z, Qiu W, Kostenuik P, Lacey DL, Simonet WS, Bolon B, Qian X, Shalhoub V, Ominsky MS, Zhu Ke H, Li X, Richards WG. Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. *Bone*. 2006; 39(4):754–766. [PubMed: 16730481]
- Li X, Grisanti M, Fan W, Asuncion FJ, Tan HL, Dwyer D, Han CY, Yu L, Lee J, Lee E, Barrero M, Kurimoto P, Niu QT, Geng Z, Winters A, Horan T, Steavenson S, Jacobsen F, Chen Q, Haldankar R, Lavalley J, Tipton B, Daris M, Sheng J, Lu HS, Daris K, Deshpande R, Valente EG, Salimi-Moosavi H, Kostenuik PJ, Li J, Liu M, Li C, Lacey DL, Simonet WS, Ke HZ, Babij P, Stolina M, Ominsky MS, Richards WG. Dickkopf-1 regulates bone formation in young growing rodents and upon traumatic injury. *J Bone Miner Res*. 2011; 26(11):2610–2621. [PubMed: 21773994]
- Li X, Liu H, Qin L, Tamasi J, Bergenstock M, Shapses S, Feyen JHM, Notterman DA, Partridge NC. Determination of Dual Effects of Parathyroid Hormone on Skeletal Gene Expression in Vivo by Microarray and Network Analysis. *J Biol Chem*. 2007; 282(45):33086–33097. [PubMed: 17690103]
- Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D'Agostin D, Kurahara C, Gao Y, Cao J, Gong J, Asuncion F, Barrero M, Warmington K, Dwyer D, Stolina M, Morony S, Sarosi I, Kostenuik PJ, Lacey DL, Simonet WS, Ke HZ, Paszty C. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. *J Bone Miner Res*. 2008; 23(6):860–869. [PubMed: 18269310]

- Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shalhoub V, Tipton B, Haldankar R, Chen Q, Winters A, Boone T, Geng Z, Niu QT, Ke HZ, Kostenuik PJ, Simonet WS, Lacey DL, Paszty C. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. *J Bone Miner Res.* 2009; 24(4):578–588. [PubMed: 19049336]
- Li X, Ominsky MS, Warmington KS, Niu QT, Asuncion FJ, Barrero M, Dwyer D, Grisanti M, Stolina M, Kostenuik PJ, Simonet WS, Paszty C, Ke HZ. Increased Bone Formation and Bone Mass Induced by Sclerostin Antibody Is Not Affected by Pretreatment or Cotreatment with Alendronate in Osteopenic, Ovariectomized Rats. *Endocrinology.* 2011; 152(9):3312–3322. [PubMed: 21733832]
- Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE, Wu D. Sclerostin Binds to LRP5/6 and Antagonizes Canonical Wnt Signaling. *J Biol Chem.* 2005; 280(20):19883–19887. [PubMed: 15778503]
- Loots GG, Kneissel M, Keller H, Baptist M, Chang J, Collette NM, Ovcharenko D, Plajzer-Frick I, Rubin EM. Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. *Genome Res.* 2005; 15(7):928–935. [PubMed: 15965026]
- MacDonald BT, Joiner DM, Oyserman SM, Sharma P, Goldstein SA, He X, Hauschka PV. Bone mass is inversely proportional to Dkk1 levels in mice. *Bone.* 2007; 41(3):331–339. [PubMed: 17613296]
- Mani A, Radhakrishnan J, Wang H, Mani A, Mani M-A, Nelson-Williams C, Carew KS, Mane S, Najmabadi H, Wu D, Lifton RP. LRP6 Mutation in a Family with Early Coronary Disease and Metabolic Risk Factors. *Science.* 2007; 315(5816):1278–1282. [PubMed: 17332414]
- Mao B, Wu W, Li Y, Hoppe D, Stannik P, Glinka A, Niehrs C. LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. *Nature.* 2001; 411(6835):321–325. [PubMed: 11357136]
- Marie P. Fibroblast growth factor signaling controlling osteoblast differentiation. *Gene.* 2003; 316:23–32. [PubMed: 14563548]
- Mayahara H, Ito T, Nagai H, Miyajima H, Tsukuda R, Taketomi S, Mizoguchi J, Kato K. In vivo stimulation of endosteal bone formation by basic fibroblast growth factor in rats. *Growth Factors.* 1993; 9(1):73–80. [PubMed: 7688520]
- Mirza FS, Padhi ID, Raisz LG, Lorenzo JA. Serum Sclerostin Levels Negatively Correlate with Parathyroid Hormone Levels and Free Estrogen Index in Postmenopausal Women. *J Clin Endocrinol Metab.* 2010; 95(4):1991–1997. [PubMed: 20156921]
- Montero A, Okada Y, Tomita M, Ito M, Tsurukami H, Nakamura T, Doetschman T, Coffin JD, Hurley MM. Disruption of the fibroblast growth factor-2 gene results in decreased bone mass and bone formation. *J Clin Invest.* 2000; 105(8):1085–1093. [PubMed: 10772653]
- Morvan F, Bouloukos K, Clément-Lacroix P, Roman Roman S, Suc-Royer I, Vayssière B, Ammann P, Martin P, Pinho S, Pognonec P, Mollat P, Niehrs C, Baron R, Rawadi G. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. *J Bone Miner Res.* 2006; 21(6):934–945. [PubMed: 16753024]
- Naganawa T, Xiao L, Abogunde E, Sobue T, Kalajzic I, Sabbieti M, Agas D, Hurley MM. In vivo and in vitro comparison of the effects of FGF-2 null and haplo-insufficiency on bone formation in mice. *Biochem Biophys Res Commun.* 2006; 339(2):490–498. [PubMed: 16298332]
- Naganawa T, Xiao L, Coffin JD, Doetschman T, Sabbieti MG, Agas D, Hurley MM. Reduced expression and function of bone morphogenetic protein-2 in bones of Fgf2 null mice. *J Cell Biochem.* 2008; 103(6):1975–1988. [PubMed: 17955502]
- Nakamura K, Kurokawa T, Aoyama I, Hanada K, Tamura M, Kawaguchi H. Stimulation of bone formation by intraosseous injection of basic fibroblast growth factor in ovariectomized rats. *Int Orthop.* 1998; 22(1):49–54. [PubMed: 9549582]
- Nakanishi R, Akiyama H, Kimura H, Otsuki B, Shimizu M, Tsuboyama T, Nakamura T. Osteoblast-targeted expression of Sfrp4 in mice results in low bone mass. *J Bone Miner Res.* 2008; 23(2):271–277. [PubMed: 17907918]
- Nakanishi R, Shimizu M, Mori M, Akiyama H, Okudaira S, Otsuki B, Hashimoto M, Higuchi K, Hosokawa M, Tsuboyama T, Nakamura T. Secreted frizzled-related protein 4 is a negative

- regulator of peak BMD in SAMP6 mice. *J Bone Miner Res.* 2006; 21(11):1713–1721. [PubMed: 17002585]
- NOF. [Accessed on January 28, 2012] National Osteoporosis Foundation. Fast Facts on Osteoporosis. <http://www.nof.org/node/40>.
- Okada Y, Montero A, Zhang X, Sobue T, Lorenzo J, Doetschman T, Coffin JD, Hurley MM. Impaired Osteoclast Formation in Bone Marrow Cultures of Fgf2 Null Mice in Response to Parathyroid Hormone. *J Biol Chem.* 2003; 278(23):21258–21266. [PubMed: 12665515]
- Ominsky MS, Li C, Li X, Tan HL, Lee E, Barrero M, Asuncion FJ, Dwyer D, Han CY, Vlasseros F, Samadfam R, Jolette J, Smith SY, Stolina M, Lacey DL, Simonet WS, Paszty C, Li G, Ke HZ. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. *J Bone Miner Res.* 2011; 26(5):1012–1021. [PubMed: 21542004]
- Onyia JE, Helvering LM, Gelbert L, Wei T, Huang S, Chen P, Dow ER, Maran A, Zhang M, Lotinun S, Lin X, Halladay DL, Miles RR, Kulkarni NH, Ambrose EM, Ma YL, Frolik CA, Sato M, Bryant HU, Turner RT. Molecular profile of catabolic versus anabolic treatment regimens of parathyroid hormone(PTH) in rat bone: an analysis by DNA microarray. *J Cell Biochem.* 2005; 95(2):403–418. [PubMed: 15779007]
- Ou G, Charles L, Matton S, Rodner C, Hurley M, Kuhn L, Gronowicz G. Fibroblast Growth Factor-2 Stimulates the Proliferation of Mesenchyme-Derived Progenitor Cells From Aging Mouse and Human Bone. *J Gerontol A Biol Sci Med Sci.* 2010; 65(10):1051–1059. [PubMed: 20643704]
- Piters E, Boudin E, Van Hul W. Wnt signaling: A win for bone. *Arch Biochem Biophys.* 2008; 473(2): 112–116. [PubMed: 18364235]
- Powers C, McLeskey S, Wellstein A. Fibroblast growth factors, their receptors and signaling. *Endocr Relat Cancer.* 2000; 7(3):165–197. [PubMed: 11021964]
- Qin L, Qiu P, Wang L, Li X, Swarthout JT, Soteropoulos P, Tolias P, Partridge NC. Gene Expression Profiles and Transcription Factors Involved in Parathyroid Hormone Signaling in Osteoblasts Revealed by Microarray and Bioinformatics. *J Biol Chem.* 2003; 278(22):19723–19731. [PubMed: 12644456]
- Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. *J Clin Invest.* 2005; 115(12):3318–3325. [PubMed: 16322775]
- Rodan S, Wesolowski G, Yoon K, Rodan G. Opposing effects of fibroblast growth factor and pertussis toxin on alkaline phosphatase, osteopontin, osteocalcin, and type I collagen mRNA levels in ROS 17/2.8 cells. *J Biol Chem.* 1989; 264(33):19934–19941. [PubMed: 2479640]
- Romero G, Sneddon WB, Yang Y, Wheeler D, Blair HC, Friedman PA. Parathyroid Hormone Receptor Directly Interacts with Dishevelled to Regulate β -Catenin Signaling and Osteoclastogenesis. *J Biol Chem.* 2010; 285(19):14756–14763. [PubMed: 20212039]
- Sabbieti MG, Agas D, Xiao L, Marchetti L, Coffin JD, Doetschman T, Hurley MM. Endogenous FGF-2 is critically important in PTH anabolic effects on bone. *J Cell Physiol.* 2009; 219(1):143–151. [PubMed: 19107841]
- Sabbieti MG, Marchetti L, Abreu C, Montero A, Hand AR, Raisz LG, Hurley MM. Prostaglandins Regulate the Expression of Fibroblast Growth Factor-2 in Bone. *Endocrinology.* 1999; 140(1): 434–444. [PubMed: 9886855]
- Silva BC, Bilezikian JP. New Approaches to the Treatment of Osteoporosis. *Annual Review of Medicine.* 2011; 62:307–322.
- Suzuki A, Ozono K, Kubota T, Kondou H, Tachikawa K, Michigami T. PTH/cAMP/PKA signaling facilitates canonical Wnt signaling via inactivation of glycogen synthase kinase-3 β in osteoblastic Saos-2 cells. *J Cell Biochem.* 2008; 104(1):304–317. [PubMed: 17990294]
- Swarthout JT, D'Alonzo RC, Selvamurugan N, Partridge NC. Parathyroid hormone-dependent signaling pathways regulating genes in bone cells. *Gene.* 2002; 282(1–2):1–17. [PubMed: 11814673]
- ten Dijke P, Krause C, de Gorter DJ, Löwik CW, van Bezooijen RL. Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling. *J Bone Joint Surg Am.* 2008; 90(Supplement 1):31–35. [PubMed: 18292354]

- Tian Y, Xu Y, Fu Q, He M. Parathyroid hormone regulates osteoblast differentiation in a Wnt/ β -catenin-dependent manner. *Mol Cell Biochem.* 2011; 355(1–2):211–216. [PubMed: 21533763]
- Tobimatsu T, Kaji H, Sowa H, Naito J, Canaff L, Hendy GN, Sugimoto T, Chihara K. Parathyroid Hormone Increases β -Catenin Levels through Smad3 in Mouse Osteoblastic Cells. *Endocrinology.* 2006; 147(5):2583–2590. [PubMed: 16484320]
- van Bezooijen RL, Roelen BA, Visser A, van der Wee-Pals L, de Wilt E, Karperien M, Hamersma H, Papapoulos SE, ten Dijke P, Löwik CW. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. *J Exp Med.* 2004; 199(6):805–814. [PubMed: 15024046]
- Van Hul W, Balemans W, Van Hul E, Dikkers FG, Obee H, Stokroos RJ, Hilderling P, Vanhoenacker F, Van Camp G, Willems PJ. Van Buchem Disease(Hyperostosis Corticalis Generalisata) Maps to Chromosome 17q12–q21. *Am J Hum Genet.* 1998; 62(2):391–399. [PubMed: 9463328]
- Van Wesenbeeck L, Cleiren E, Gram J, Beals RK, Bénichou O, Scopelliti D, Key L, Renton T, Bartels C, Gong Y, Warman ML, De Vernejoul MC, Bollerslev J, Van Hul W. Six Novel Missense Mutations in the LDL Receptor-Related Protein 5(LRP5) Gene in Different Conditions with an Increased Bone Density. *Am J Hum Genet.* 2003; 72(3):763–771. [PubMed: 12579474]
- Vokes, TJ.; Favus, MJ. Clinical Management of the Patient with Osteoporosis. In: Robertson, RP., editor. *Translational Endocrinology & Metabolism-Osteoporosis Update.* Maryland: The Endocrine Society; 2010. p. 9-31.
- Wan M, Yang C, Li J, Wu X, Yuan H, Ma H, He X, Nie S, Chang C, Cao X. Parathyroid hormone signaling through low-density lipoprotein-related protein 6. *Genes Dev.* 2008; 22(21):2968–2979. [PubMed: 18981475]
- Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, Appleby M, Brunkow ME, Latham JA. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. *EMBO J.* 2003; 22(23):6267–6276. [PubMed: 14633986]
- Xiao G, Jiang D, Gopalakrishnan R, Franceschi RT. Fibroblast growth factor 2 induction of the osteocalcin gene requires MAPK activity and phosphorylation of the osteoblast transcription factor, Cbfa1/Runx2. *J Biol Chem.* 2002; 277(39):36181–36187. [PubMed: 12110689]
- Xiao L, Sobue T, Eslinger A, Kronenberg MS, Coffin JD, Doetschman T, Hurley MM. Disruption of the Fgf2 gene activates the adipogenic and suppresses the osteogenic program in mesenchymal marrow stromal stem cells. *Bone.* 2010; 47(2):360–370. [PubMed: 20510392]
- Xiao L, Liu P, Li X, Doetschman T, Coffin JD, Drissi H, Hurley MM. Exported 18-kDa isoform of fibroblast growth factor-2 is a critical determinant of bone mass in mice. *J Biol Chem.* 2009; 284(5):3170–3182. [PubMed: 19056741]
- Yang X, Matsuda K, Bialek P, Jacquot S, Masuoka HC, Schinke T, Li L, Brancorsini S, Sassone-Corsi P, Townes TM, Hanauer A, Karsenty G. ATF4 Is a Substrate of RSK2 and an Essential Regulator of Osteoblast Biology: Implication for Coffin-Lowry Syndrome. *Cell.* 2004; 117(3):387–398. [PubMed: 15109498]
- Yao GQ, Wu JJ, Troiano N, Insogna K. Targeted overexpression of Dkk1 in osteoblasts reduces bone mass but does not impair the anabolic response to intermittent PTH treatment in mice. *J Bone Miner Metab.* 2011; 29(2):141–148. [PubMed: 20602130]
- Yao W, Cheng Z, Shahnazari M, Dai W, Johnson ML, Lane NE. Overexpression of secreted frizzled-related protein 1 inhibits bone formation and attenuates parathyroid hormone bone anabolic effects. *J Bone Miner Res.* 2010; 25(2):190–199. [PubMed: 19594295]
- Yu S, Franceschi RT, Luo M, Fan J, Jiang D, Cao H, Kwon TG, Lai Y, Zhang J, Patrene K, Hankenson K, Roodman GD, Xiao G. Critical Role of Activating Transcription Factor 4 in the Anabolic Actions of Parathyroid Hormone in Bone. *PLoS ONE.* 2009; 4(10):e7583. [PubMed: 19851510]
- Yu S, Franceschi RT, Luo M, Zhang X, Jiang D, Lai Y, Jiang Y, Zhang J, Xiao G. Parathyroid Hormone Increases Activating Transcription Factor 4 Expression and Activity in Osteoblasts: Requirement for Osteocalcin Gene Expression. *Endocrinology.* 2008; 149(4):1960–1968. [PubMed: 18187540]

Figure 1.

Osteoblast differentiation from mesenchymal stem cell to mature osteoblast is regulated by transcriptions factors. (Adapted from (Franceschi, et al., 2007))

Figure 2. Intermittent PTH administration stimulates osteoblast differentiation and bone formation through multiple mechanisms (Adapted from (Jilka, 2007)).

Figure 3. Bone anabolic effect of PTH is mediated by signaling of extracellular factors, such as FGF2 and Wnt signaling.